Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022GlobeNewsWire • 04/06/22
Biomea Fusion to Present at Oppenheimer's 32nd Annual Virtual Healthcare ConferenceGlobeNewsWire • 03/15/22
Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022GlobeNewsWire • 03/14/22
Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022GlobeNewsWire • 03/08/22
Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate HighlightsGlobeNewsWire • 02/28/22
Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical OfficerGlobeNewsWire • 02/01/22
Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect ConferenceGlobeNewsWire • 01/11/22
Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and in Diabetes for BMF-219GlobeNewsWire • 01/10/22
Biomea Fusion Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 11/03/21
Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219GlobeNewsWire • 09/16/21
Biomea Fusion Reports Second Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 08/11/21
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial OfficerGlobeNewsWire • 06/28/21
Biomea Fusion Reports First Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 05/27/21